Type 2 Diabetic Patients Maintained on Statin Therapy
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
Patients with diabetes mellitus (DM) are at increased risk of atherosclerotic cardiovascular
disease (ACVD). The achievement of the LDL-C target with statins for the reduction of ACVD
risk is recommended. However, the risk is still present. Therefore, we investigated the
impact of high sensitivity C-reactive protein (hsCRP), sortilin, adiponectin and leptin
biomarkers that linking inflammatory hypothesis of diabetes mellitus and atherosclerosis in
diabetic patients treated with rosuvastatin and atrovastatin. Methods: Based on exclusion
criteria, 150 type 2 diabetic patients were eligible and randomly assigned to receive either
40 mg per day atorvastatin (ATROVA group, n= 80) or 10 mg per day rosuvastatin (ROSUVA group,
n= 80) for 6 months.